Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
AAPS PharmSciTech ; 1(3): E20, 2000 Jul 02.
Article in English | MEDLINE | ID: mdl-14727906

ABSTRACT

The purpose of this investigation was to develop a rapidly disintegrating calcium carbonate (CC) tablet by direct compression and compare it with commercially available calcium tablets. CC tablets were formulated on a Carver press using 3 different forms of CC direct compressed granules (Cal-Carb 4450, Cal-Carb 4457, and Cal-Carb 4462). The breaking strength was measured using a Stokes-Monsanto hardness tester. The disintegration and dissolution properties of the tablets were studied using USP methodology. The calcium concentration was determined by an atomic absorption spectrophotometer. Scanning electron microscopy was used to evaluate the surface topography of the granules and tablets. Breaking strength of Cal-Carb 4450, Cal-Carb 4457, and Cal-Carb 4462 tablets was in the range of 7.2 to 7.7 kg, as compared with a hardness of 6.2 kg and 10 kg for the commercially available calcium tablets Citracal and Tums, respectively. The disintegration time for the tablets presented in the order earlier was 4.1, 2.1, 1.9, 2.9, and 9.7 minutes, respectively. The dissolution studies showed that all formulations released 100% of the elemental calcium in simulated gastric fluid in less than 20 minutes. In summary, this study clearly demonstrated that quick disintegrating CC tablets can be formulated without expensive effervescence technology.


Subject(s)
Calcium Carbonate/chemistry , Calcium Carbonate/metabolism , Tablets/chemistry , Tablets/metabolism , Chemistry, Pharmaceutical , Drug Compounding , Evaluation Studies as Topic , Solubility , Time Factors
2.
Nat Med ; 2(2): 224-9, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8574969

ABSTRACT

Mutations in two recently identified genes appear to cause the majority of early-onset familial Alzheimer's disease (FAD). These two novel genes, presenilin 1 (PS1) and presenilin 2 (PS2) are members of an evolutionarily conserved gene family. The normal biological role(s) of the presenilins and the mechanism(s) by which the FAD-associated mutations exert their effect remain unknown. Employing in situ hybridization, we demonstrate that the expression patterns of PS1 and PS2 in the brain are extremely similar to each other and that messages for both are primarily detectable in neuronal populations. Immunochemical analyses indicate that PS1 and PS2 are similar in size and localized to similar intracellular compartments (endoplasmic reticulum and Golgi complex). FAD-associated mutations in PS1 and PS2 do not significantly modify either their migration patterns on SDS-polyacrylamide gel electrophoresis or their overall subcellular localization, although subtle differences in perinuclear staining were noted for mutant PS1.


Subject(s)
Alzheimer Disease/metabolism , Brain/metabolism , Cell Membrane/metabolism , Presenilin-2/analysis , Aged , Alzheimer Disease/pathology , Animals , Base Sequence , Biomarkers , Brain/pathology , Brain/ultrastructure , Cell Compartmentation , Humans , In Situ Hybridization , Middle Aged , Molecular Sequence Data , Mutation , Neurons/metabolism , Neurons/pathology , Presenilin-1 , Presenilin-2/genetics , RNA Probes , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...